PULM, US7458481014

Analysts set USD 3.50 target for Pulmonx stock, 96.63 percent above price

Published on 10/17/2026 at 22:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Revenue was USD 22.76 million in second-quarter 2026. Pulmonx stock costs USD 1.78 on October 16, 2026, down 3.78 percent on Nasdaq.

Analyst view and results

  • On October 7, 2026, four analysts gave Pulmonx an average USD 3.50 target, 96.63 percent above the price.
  • Second-quarter revenue was USD 22.76 million and net loss was USD 10.08 million for the period ending June 30, 2026.
  • Pulmonx stock was last at USD 1.78 on October 16, 2026 at 4:00 p.m. ET, down 3.78 percent versus the Nasdaq prior close.
  • Pulmonx is scheduled to report third-quarter 2026 results on October 27, 2026.
PULM, US7458481014, Illustration mit AI erstellt.

Four analysts put Pulmonx's average price target at USD 3.50, 96.63 percent above the Nasdaq price of USD 1.78 on October 16, 2026, according to Rallies. The stock was last at USD 1.78 on October 16, 2026 at 4:00 p.m. ET, down 3.78 percent versus the Nasdaq prior close of October 15, 2026.

Second-quarter numbers

Pulmonx entered the October market discussion with a recent quarterly loss and revenue base. TradingView lists second-quarter 2026 revenue at USD 22.76 million and net loss at USD 10.08 million for the period ended June 30, 2026. The figures give investors two reference points for the next update: commercial growth and the cost of maintaining the rollout of the Zephyr Endobronchial Valve.

Price position on Nasdaq

The October 16 Nasdaq session left Pulmonx 22.61 percent lower year to date, according to the dated market metrics carried by Rallies. The finance quote put the 52-week range at USD 1.13 to USD 2.89, placing the latest price 38.41 percent below the high and 57.52 percent above the low. Trading volume was 243,987 shares against an average of 490,687 shares on October 16, 2026.

Valuation and next date

The market capitalization was USD 76.4 million on October 16, 2026, while the trailing price-to-earnings ratio was negative 1.55 and the dividend yield was 0.00 percent. Rallies reported a consensus of three buy ratings and one hold among four analysts on October 7, 2026, alongside the USD 3.50 average target. Pulmonx is scheduled to report third-quarter 2026 results on October 27, 2026, after the close, with its conference call at 4:30 p.m. ET, according to GlobeNewswire.

Comparison with peers

Pulmonx (Nasdaq, USD): minus 3.78 percent, P/E -1.55, market capitalization USD 76.4 million
Inspire Medical Systems (Nasdaq, USD): minus 1.90 percent, P/E 14.89, market capitalization USD 2.0 billion
PROCEPT BioRobotics (Nasdaq, USD): minus 3.20 percent, P/E -9.06, market capitalization USD 1.0 billion

Closing price context

Pulmonx remains a small-cap medical-device company whose valuation is being measured against a sizeable analyst target gap and a scheduled results date. The next quarterly release will provide the next dated test of revenue and loss trends.

Pulmonx stock facts

  • Company: Pulmonx Corporation
  • ISIN: US7458481014
  • Ticker: LUNG
  • Primary exchange: Nasdaq
  • Price Nasdaq as of October 16, 2026, 4:00 p.m. ET: USD 1.78
  • Change versus Nasdaq prior close: minus 3.78 percent
  • Market capitalization: USD 76.4 million (as of October 16, 2026)
  • 52-week range: USD 1.13-2.89 (as of October 16, 2026)
  • Sector / Industry: Healthcare / Medical Devices
  • Next earnings date: October 27, 2026

Market context: Market report Nasdaq Composite.

More news and analyses on Pulmonx stock

Disclaimer...
en | US7458481014 | PULM | boerse | 70351294 | bgmi